Streetbeat News

Price Targets

DUK

JP Morgan analyst Christopher Turnure maintains a Neutral rating on Duke Energy (NYSE:DUK) and raises the price target from $111 to $120.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:10 pm

PGY

JMP Securities analyst David Scharf has reiterated a Market Outperform rating on Pagaya Techs (NASDAQ:PGY) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:10 pm

AIG

Keefe, Bruyette & Woods analyst Meyer Shields maintains an Outperform rating on American International Group (NYSE:AIG) but lowers the price target from $96 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:08 pm

D

JP Morgan analyst Jeremy Tonet maintains a Neutral rating on Dominion Energy (NYSE:D) and raises the price target from $54 to $57.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:08 pm

KURA

JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:08 pm

CCOI

JP Morgan analyst Sebastiano Petti maintains a Neutral rating on Cogent Comms Hldgs (NASDAQ:CCOI) and raises the price target from $70 to $76.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:07 pm

PAYO

Payoneer Global shares are trading higher after the company announced it began to purchase all of its outstanding public warrants and some common stock at a price of $0.78 per share. Additionally, Citigroup maintained a Buy rating on the stock and raised its price target from $7 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:06 pm

AQST

JMP Securities analyst Jason Butler has reiterated a Market Outperform rating for Aquestive Therapeutics (NASDAQ:AQST) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:06 pm

WBTN

Evercore ISI Group analyst Mark Mahaney maintains an Outperform rating on Webtoon Entertainment (NASDAQ:WBTN) but lowers the price target from $30 to $27.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:05 pm

RNA

Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $45 to $54.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:04 pm